Abstract
Non-alcoholic fatty liver disease (NAFLD) is a challenge not only due to its rising prevalence but also, and perhaps more importantly, due to the lack of sustainable treatment options. Intestinal microbiota are thought to participate in the development and progression of NAFLD and their manipulation is, hence, being investigated as a treatment aim. This review summarizes the involvement of intestinal microbiota in the pathogenesis on NAFLD. In addition, we synthesize the results of the most recent animal and human studies aimed at treating dysbiosis seen in patients with NAFLD. Lastly, we review the evidence regarding the efficacy of manipulating short chain fatty acid and bile acid signaling in the treatment of NAFLD.
Keywords: Bile acids, dysbiosis, fatty liver, microbiota, NAFLD, NASH.
Current Drug Targets
Title:Targeting the Gut Microbiota for the Treatment of Non-Alcoholic Fatty Liver Disease
Volume: 16 Issue: 12
Author(s): Marialena Mouzaki and Robert Bandsma
Affiliation:
Keywords: Bile acids, dysbiosis, fatty liver, microbiota, NAFLD, NASH.
Abstract: Non-alcoholic fatty liver disease (NAFLD) is a challenge not only due to its rising prevalence but also, and perhaps more importantly, due to the lack of sustainable treatment options. Intestinal microbiota are thought to participate in the development and progression of NAFLD and their manipulation is, hence, being investigated as a treatment aim. This review summarizes the involvement of intestinal microbiota in the pathogenesis on NAFLD. In addition, we synthesize the results of the most recent animal and human studies aimed at treating dysbiosis seen in patients with NAFLD. Lastly, we review the evidence regarding the efficacy of manipulating short chain fatty acid and bile acid signaling in the treatment of NAFLD.
Export Options
About this article
Cite this article as:
Mouzaki Marialena and Bandsma Robert, Targeting the Gut Microbiota for the Treatment of Non-Alcoholic Fatty Liver Disease, Current Drug Targets 2015; 16 (12) . https://dx.doi.org/10.2174/1389450116666150416120351
DOI https://dx.doi.org/10.2174/1389450116666150416120351 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cachexia and Herbal Medicine: Perspective
Current Pharmaceutical Design Drug-Induced Aseptic Meningitis
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Platelet Count and IgE Level in Chronic Idiopathic Urticaria: A Case-control Study
Recent Advances in Inflammation & Allergy Drug Discovery Anaplastic Lymphoma Kinase as a Therapeutic Target in Anaplastic Large Cell Lymphoma, Non-Small Cell Lung Cancer and Neuroblastoma
Anti-Cancer Agents in Medicinal Chemistry PACAP is Implicated in the Stress Axes
Current Pharmaceutical Design Inflammation: A Multidimensional Insight on Natural Anti-Inflammatory Therapeutic Compounds
Current Medicinal Chemistry Diuretics: From Classical Carbonic Anhydrase Inhibitors to Novel Applications of the Sulfonamides
Current Pharmaceutical Design Cardiovascular Effects of Omega-3 Free Fatty Acids.
Current Vascular Pharmacology Emerging Risk Factors for Cerebrovascular Disease
Current Drug Targets Development of a Novel Nanocomposite Based on Reduced Graphene Oxide/Chitosan/Au/ZnO and Electrochemical Sensor for Determination of Losartan
Current Analytical Chemistry Amyloid Forming Proteases: Therapeutic Targets for Alzheimers Disease
Current Pharmaceutical Design Microglia Phenotype Diversity
CNS & Neurological Disorders - Drug Targets miRNAs in Alzheimer Disease – A Therapeutic Perspective
Current Alzheimer Research Relationship Between Proinsulin Level and Cardiovascular Risk Factors Clustering: An Epidemiological Study
Vascular Disease Prevention (Discontinued) Insulin-Like Growth Factor-1 and its Derivatives: Potential Pharmaceutical Application for Treating Neurological Conditions
Recent Patents on CNS Drug Discovery (Discontinued) Editorial: Steroid-Dependent Management of Biological Responses in the Nervous System
CNS & Neurological Disorders - Drug Targets Gene Expression Profiling as a Tool for Positional Cloning of Genes- Shortcut or the Longest Way Round
Current Genomics MicroRNAs: A Critical Regulator and a Promising Therapeutic and Diagnostic Molecule for Diabetic Cardiomyopathy
Current Gene Therapy Hydrogen Sulfide and Endothelial Dysfunction: Relationship with Nitric Oxide
Current Medicinal Chemistry Resveratrol Counteracts Hypoxia-Induced Gastric Cancer Invasion and EMT through Hedgehog Pathway Suppression
Anti-Cancer Agents in Medicinal Chemistry